153 related articles for article (PubMed ID: 34819618)
1. Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis.
Dong Y; Tang BX; Wang Q; Zhou LW; Li C; Zhang X; Sun DD; Sun X; Zhang XM; Xiong B; Li J; Shi H; Chen DQ; Zang Y
Acta Pharmacol Sin; 2022 Jul; 43(7):1769-1779. PubMed ID: 34819618
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction.
Yu WK; Chen WC; Su VY; Shen HC; Wu HH; Chen H; Yang KY
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897764
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
4. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Ahangari F; Becker C; Foster DG; Chioccioli M; Nelson M; Beke K; Wang X; Justet A; Adams T; Readhead B; Meador C; Correll K; Lili LN; Roybal HM; Rose KA; Ding S; Barnthaler T; Briones N; DeIuliis G; Schupp JC; Li Q; Omote N; Aschner Y; Sharma L; Kopf KW; Magnusson B; Hicks R; Backmark A; Dela Cruz CS; Rosas I; Cousens LP; Dudley JT; Kaminski N; Downey GP
Am J Respir Crit Care Med; 2022 Dec; 206(12):1463-1479. PubMed ID: 35998281
[No Abstract] [Full Text] [Related]
5. Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1
Wang Q; Tang B; Sun D; Dong Y; Ji Y; Shi H; Zhou L; Yang Y; Luo M; Tan Q; Chen L; Dong Y; Li C; Xie R; Zang Y; Shen J; Xiong B; Li J; Chen D
Acta Pharm Sin B; 2022 Apr; 12(4):1943-1962. PubMed ID: 35847490
[TBL] [Abstract][Full Text] [Related]
6. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.
Wang Y; Liu H; Li W; Xie Y; Gan C; Xue T; Su X; Yue L; Wang Q; Fan C; Zhang Y; Ye T
Eur J Med Chem; 2023 Jan; 246():114953. PubMed ID: 36463728
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice.
Miao Y; Wang Y; Bi Z; Huang K; Gao J; Li X; Li S; Wei L; Zhou H; Yang C
BMC Pulm Med; 2023 Mar; 23(1):94. PubMed ID: 36949426
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X
Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272
[TBL] [Abstract][Full Text] [Related]
11. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
13. Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury.
van Gijsel-Bonnello M; Darling NJ; Tanaka T; Di Carmine S; Marchesi F; Thomson S; Clark K; Kurowska-Stolarska M; McSorley HJ; Cohen P; Arthur JSC
J Biol Chem; 2022 Dec; 298(12):102644. PubMed ID: 36309093
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
18. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
20. Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.
Fu S; Wen Y; Peng B; Tang M; Shi M; Liu J; Yang Y; Si W; Guo Y; Li X; Yan T; Kang J; Pei H; Chen L
Bioorg Chem; 2023 Aug; 137():106539. PubMed ID: 37163811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
